Schedule an appointment to review your reasons for discontinuation, current glycaemic control (recent HbA1c and glucose readings), and overall diabetes management plan
The December 2024 expansion of the MDL to include Saxenda, another GLP-1 medication, demonstrates the litigations growing scope while the courts rejection of blood clot claims shows judicial efforts to maintain manageable boundaries
Lantus must not be given with an insulin pump, or mixed with other insulins
Mechanism With Real Numbers What Most Pages Get Wrong About Oral BPC-157 The Chemistry Behind Capsule Stability and Storage Rules Honest Head-to-Head: Capsules vs
GLP-1 receptor / COYA 301 + GLP-1 receptor agonist combination / Inflammatory diseasesUndisclosedDiscoveryactive COYA 201COYA 201 / Allogeneic Treg-derived exosomes / UndisclosedUndisclosedPreclinicalactive COYA 206COYA 206 / Antigen-directed allogeneic Treg-derived exosomes / UndisclosedUndisclosedPreclinicalactive 5assets EB613EB613 / PTH 1-34, teriparatide / oral peptide tablet / OsteoporosisPostmenopausal women with low BMD and high-risk osteoporosisPhase 3Phase 3 protocol submitted to FDA
The program is designed to gradually scale up to higher doses over time only if needed, offering a more dynamic, personalized path compared to the standard aggressive titration schedules
